Abstract
Advances in molecular genetic research are leading to an ever expanding appreciation of the potential role of genetic variation in predisposition to disease. Although initial work focused on single genetic defects in diseases such as Huntington’s chorea [1, 2] and Alzheimer’s disease [3], recent discoveries have provided insight into susceptibility of a wide range of conditions including many cancers [4–6] and autoimmune inflammatory conditions [7–10]. These observations in autoimmune inflammatory conditions stimulated research into the possibility that there may be an important genetic component to the development and course of infection and sepsis [11–17].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Petersen A, Mani K, Brundin P (1999) Recent advances on the pathogenesis of Huntington’s disease. Exp Neurol 157: 1–18
Nance MA (1998) Huntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol 11: 61–70
de Knijff P, van Duijn CM (1998) Role of APOE in dementia: A Critical reappraisal. Haemostasis 28: 195–201
Kamataki T, Nunoya K, Sakai Y, et al (1999) Genetic polymorphism of CYP2A6 in relation to cancer. Mutat Res 428: 125–130
Inatomi H, Katoh T, Kawamoto T, Matsumoto T (1999) NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 6: 446–454
Edwards SM, Badzioch MD, Minter R, et al (1999) Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 84: 458–465
Cantagrel A, Navaux F, Loubet-Lescoulie P, et al (1999) Interleukin-1 beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 42: 1093–1100
Dijstelbloem HM, Scheepers RH, Oost WW, et al (1999) Fcgamma receptor polymorphisms in Wegener’s granulomatosis: risk factors for disease relapse. Arthritis Rheum 42: 1823–1827
Atsumi T, Tsutsumi A, Amengual O, et al (1999) Correlation between beta2-glycoprotein I valine/leucine247 polymorphism and anti-beta2-glycoprotein I antibodies in patients with primary antiphospholipid syndrome. Rheumatology (Oxford) 38: 721–723
Fukazawa T, Yabe I, Kikuchi S, et al (1999) Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 166: 47–52
Nadel S, Newport MJ, Booy R, Levin M (1996) Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 174: 878–880
Stuber F, Udalova IA, Book M, et al (1995) -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 461: 42–50
Stuber F, Petersen M, Bokelmann F, Schade U (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24: 381–384
Schroeder S, Reck M, Hoeft A, Stuber F (1999) Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis. Crit Care Med 27: 1265–1270
Fang XM, Schroder S, Hoeft A, Stuber F (1999) Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 27: 1330–1334
Majetschak M, Flohe S, Obertacke U, et al (1999) Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230: 207–214
Mira JP, Cariou A, Grail F, et al (1999) Association of TNF2, a TNF-a promoter polymorphism, with septic shock susceptibility and mortality. A multicenter study. JAMA 282: 561–568
Natanson C, Esposito CJ, Banks SM (1998) The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26: 1927–1931
Bogardus STJ, Concato J, Feinstein AR (1999) Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA 281: 1919–1926
Brown PO, Botstein D (1999) Exploring the new world of the genome with DNA microarrays. Nat Genet 21: Suppl-7
Santis G, Evans TW (1999) Molecular biology for the critical care physician. Part II: where are we now? Crit Care Med 27: 997–1003
Santis G, Evans TW (1999) Molecular biology for the critical care physician part I: terminology and technology. Crit Care Med 27: 825–831
Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340: 207–214
Nakashima H, Inoue H, Akahoshi M, et al (1999) The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEBS Lett 453: 187–190
Tsukamoto K, Emi M (1998) A polymorphic CA repeat sequence at the human calcitonin locus. J Hum Genet 43: 146–147
Kumar A, Short J, Parrillo JE (1999) Genetic factors in septic shock. JAMA 282: 579–581
Roberts R (1997) Rapid MB CK subform assay and the early diagnosis of myocardial infarction. Clin Lab Med 17: 669–683
Puleo PR, Roberts R (1988) An update on cardiac enzymes. Cardiol Clin 6: 97–109
Li D, Zhao L, Liu M, et al (1999) Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am Heart J 137: 1145–1152
Tracey KJ, Fong Y, Hesse DG, et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664
Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771–778
Remick D, Manohar P, Bolgos G, et al (1995) Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4: 89–95
Echtenacher B, Falk W, Mannel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145: 3762–3766
Wang H, Bloom O, Zhang M, et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251
Jepson AP, Banya WA, Sisay-Joof F, et al (1995) Genetic regulation of fever in Plasmodium falciparum malaria in Gambian twin children. J Infect Dis 172: 316–319
Bernal W, Donaldson P, Wendon J (1999) Pro-inflammatory cytokine genomic polymorphism and critical illness. In: Vincent JL, editor. 1999 Yearbook of Intensive Care and Emergency Medicine, Springer, Heidelberg, pp 10–18
Pritchard JK, Rosenberg NA (1999) Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65: 220–228
Muckart DJ, Bhagwanjee S (1997) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25: 1789–1795
Bone RC, Balk RA, Cerra FB, et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–1655
Vincent JL (1995) Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 25: 372–374
Perl TM, Dvorak L, Hwang T, Wenzel RP (1995) Long-term survival and function after suspected gram-negative sepsis. JAMA 274: 338–345
Knaus WA, Harrell FEJ, LaBrecque JF, et al (1996) Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-Ira Phase III Sepsis Syndrome Study Group. Crit Care Med 24: 46–56
Vincent JL, Moreno R, Takala J, et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis- Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22: 707–710
Bowcock A, Cavalli-Sforza L (1991) The study of variation in the human genome. Genomics 11: 491–498
Cann HM (1998) Human genome diversity. C R Acad Sci III 321: 443–446
Chakravarti A (1999) Population genetics–making sense out of sequence. Nat Genet 21: 56–60
Zellweger R, Wichmann MW, Ayala A, et al (1997) Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 25: 106–110
Wichmann MW, Zellweger R, DeMaso CM, et al (1996) Mechanism of immuno-suppression in males following trauma-hemorrhage. Critical role of testosterone. Arch Surg 131: 1186–1191
Quartin AA, Schein RM, Kett DH, Peduzzi PN, for the Dept of Veterans Affairs Systemic Sepsis Cooperative Studies Group (1997) Magnitude and duration of the effect of sepsis on survival. JAMA 277: 1058–1063
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wax, R.S., Angus, D.C. (2000). The Molecular Genetics of Sepsis: Clinical Epidemiology Considerations. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 2000. Yearbook of Intensive Care and Emergency Medicine, vol 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-13455-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-13455-9_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66830-5
Online ISBN: 978-3-662-13455-9
eBook Packages: Springer Book Archive